SeaStar Medical Holding Corp

Research SeaStar Medical Holding Corp (ICU) on Bullrun: market cap USD 13.55M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 13.55M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 1.23M-USD 12.15M-USD 13.60M95.7%-8.3USD 11.98MUSD 525.00KUSD 10.42M
FY2024USD 135.00K-USD 24.83M-USD 16.01M100.0%-6.63USD 1.82MUSD 574.00K-USD 2.18M
FY2023USD 0-USD 26.23Mn/an/a-30.26USD 176.00KUSD 4.71M-USD 13.87M
FY2022n/a-USD 12.19Mn/an/a-1.48USD 47.00KUSD 8.83M-USD 20.76M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 13.55Mn/an/an/a
20252025-12-31USD 9.23Mn/an/an/a
20242024-12-31USD 11.60Mn/an/an/a
20232023-12-29USD 19.71Mn/an/an/a
20222022-12-30USD 52.07Mn/an/an/a
20212021-12-31n/a1172.9n/an/a

About SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is SeaStar Medical Holding Corp's market cap?

SeaStar Medical Holding Corp's market capitalization is USD 13.55M.

What does SeaStar Medical Holding Corp do?

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.